College of Fellows

The College of Fellows recognizes CRS members who have made outstanding contributions to the field of delivery science and technology over a minimum of 10 years. Contributions may have been technical, scientific, and/or managerial in one or more fields of research, commercial development, education, and/or leadership within the areas of interest to CRS. Fellowship is the most prestigious level of membership in CRS.

2017 College of Fellows

 

Hongming Chen is the Chief Scientific Officer at Kala Pharmaceuticals, a biotech company she helped to start in 2010. At Kala, she successfully translated a novel nanoparticle technology from bench discovery to Phase III clinical trials, and has helped to attract >$150MM investment to the company. Dr. Chen joined Kala from TransForm Pharmaceuticals, another biotech company she helped to start and build. TransForm was acquired by Johnson & Johnson in 2005 for $230 million. Before TransForm, Dr. Chen held various research positions at AstraZeneca and Merck. In 2014, Mass High Tech named Dr. Chen as one of its Women to Watch. She was also profiled by the C&E News in “Startup Hurdles” as one of the successful women entrepreneurs. In 2015, Dr. Chen was elected to the College of Fellows of the American Institute for Medical and Biological Engineering. Dr. Chen currently serves on the review panel for the NIH Small Business “Biomaterials, Delivery, and Nanotechnology” Section and she chairs the Chapter Engagement Task Force for CRS. Dr. Chen received her B.S. in chemical engineering from University of Texas at Austin in 1992, and her Master and Sc.D. in chemical engineering from MIT in 1995 and 1996, respectively.

 

Sevda Şenel is a full Professor of Pharmaceutical Technology at the School of Pharmacy at Hacettepe University, Ankara Turkey. Dr. Şenel continued her research at highly prestigious centers including Leiden University, University of Strathclyde, University of Iowa, University of South-Paris, London School of Pharmacy, CSIRO-Livestock Industries, Australia and InterAg, New Zealand. Numerous international (NATO-CRG, NATO-CLG, British Council, EU-7-SME) and national (TUBITAK, SAN-TEZ) projects led her group to the development of non-invasive systems for drugs and vaccines via various mucosae (buccal, sublingual and nasal) in human and veterinary field. Dr. Şenel and her research group has been awarded a number of prestigious honors including AAPS-PharmSciTech Best Poster Award (2015), Hacettepe University Science Award (2011), The Distinguished Scientist Award by the Academy of Science of the Turkish Pharmacists Association (2010), CRS-Intervet Best Veterinary Paper Award (2005) and the Novartis Pharmaceutical Technology Research Award (2004). Dr. Şenel is the author of more than 150 research publications, which includes original research and book chapters. She was the president of the European Chitin Society (2009–2013), served on the CRS Board of Scientific Advisors (2006–2009), and served on the CRS Young Scientists Committee and CRS Animal Health and Preclinical Sciences Division. She is currently member of the CMC committee for vaccines at the Turkish Medicines and Medical Device Agency (TITCK).

 

Patrick J. Sinko is a Pharmacist and a Pharmaceutical Scientist at Rutgers, The State University of New Jersey. He holds the rank of Distinguished Professor (II) and is the Parke-Davis Endowed Chair in Pharmaceutics and Drug Delivery in the Ernest Mario School of Pharmacy. Dr. Sinko has authored or coauthored over 450 research papers, abstracts and book chapters. He was elected Fellow in both the American Association for the Advancement of Science and American Association of Pharmaceutical Scientists.  Dr. Sinko was also elected to serve on the Council of the AAAS and the Board of Scientific Advisors of the Controlled Release Society and was the Founding Chair of the AAPS Nanotechnology Focus Group.  He is the Principal Investigator of an active research laboratory that focuses on biopharmaceutics, pharmaceutical formulations and molecular-, nano- and micro-scale drug delivery with specific applications to the treatment or prevention of HIV/AIDS, breast and lung cancer, chemical terrorism countermeasures and TB.  During his career, Dr. Sinko has received several awards for his teaching and research, including the Rutgers University Board of Trustees Award for Excellence in Research and highly selective National Institutes of Health FIRST and MERIT Awards.

Kathryn E. Uhrich is a distinguished polymer chemist, whose innovative research on polymers for controlled release applications has advanced the field. She currently serves as Dean of the College of Natural and Agricultural Sciences at the University of California, Riverside and serves as editor-in-chief of the Journal of Bioactive and Compatible Polymers. Dr. Uhrich’s research links chemistry with the life sciences and engineering disciplines to create bioactive, biodegradable polymers and devices for use in drug delivery, food safety and personal care. For this research, she has been issued nearly 100 U.S. and international patents, and her work has spawned several start-up companies. Over her career, Dr. Uhrich has supervised more than 60 graduate students and 80 undergraduate students as well as mentoring nearly 40 senior researchers in her lab. Dr. Uhrich has authored more than 160 peer-reviewed articles and given more than 290 invited presentations, generated nearly $30 million in federal and corporate research funding, collaborated extensively with colleagues in the U.S. and overseas, and worked in close partnership with several companies. Uhrich earned her Ph.D. in organic chemistry from Cornell University, and her B.S. in chemistry, with honors, from the University of North Dakota.

Ernst Wagner is professor of Pharmaceutical Biotechnology at Ludwig-Maximilians-Universität Munich since 2001, member of the Center for Nanoscience (CeNS), and biomedical nanotechnology area coordinator of the Cluster of Excellence ‘Nanosystems Initiative Munich’. For 29 years he has contributed to the area of polymer-based nucleic acid delivery. Since 1988 as Group Leader at the Institute of Molecular Pathology, Vienna, he developed synthetic virus-like gene transfer systems, including adenovirus-enhanced transferrinfection (AVET), which led to the development of the first-in-world polymer-based clinical gene therapy study (IL-2 gene-modified cancer vaccines) in 1994, and his parallel function as Director for Cancer Vaccines at Boehringer Ingelheim (1992-2001). His current research focuses on chemical evolution of sequence-defined carriers for drugs, proteins and therapeutic nucleic acids, with biomedical focus on tumor-targeted therapies. Ernst Wagner has authored ≥410 publications (h-index 73). He is Editor-in Chief of The Journal of Gene Medicine, and Editor of Pharmaceutical Research, Board member of the German Society for Gene Therapy, Committee member of the ASGCT. He has been member of the T. Nagai Postdoctoral Research Achievement award committee and the BSA of the CRS, invited guest professor at Utrecht University (1996), Fudan University (2012-13), and Sichuan University (2014-17).

2018 Award Criteria:

Elevation from ‘member’ to ‘fellow’ recognizes an exceptional CRS member who has made outstanding and sustained contributions to the field of delivery science and technology. In considering nominations for fellow status, the College of Fellows Selection Committee will consider the length, breadth, depth, and impact of the achievements. Fellow candidates working in academia, industry, governmental agencies, and representative of all demographic groups are selected from every area of delivery science and technology. Fellows should have distinguished themselves as leaders in their field through impactful contributions in fundamental or applied research, technology, products, and/or education within the areas of interest of the CRS. Service and leadership within CRS will be considered, but is not a requirement for election to the College of Fellows.

Individuals accepting nomination to the CRS College of Fellows agree not only to accept the honor of recognition of excellence, but also to make active contributions to the society through their involvement in CRS-sponsored activities. 

Documentation of excellence includes contributions to one or more of the following:

  • Significant advances in the technical and scientific aspects of fields related to delivery science and technology
  • Significant advances in the regulatory areas of delivery science and technology
  • Translation of delivery science and technology into commercial products and/or services which benefit society

Nomination Process:

A nomination must be submitted by a member of CRS. A CRS member may nominate only one (1) person for Fellow in each annual call. In addition, there must be a supporting letter written by the nominator and one (1) additional member of the CRS.

Election to the College of Fellows is only available to current members of CRS who are at the level of full professor or at an equivalent rank for individuals working in industry or governmental agencies. Fellowship is the most prestigious level of membership of the CRS and hence, a maximum of five (5) new Fellowships will be awarded every year.

Nominations for the 2018 awards are now being sought.

Nomination Packet Requirements:

In addition to completing the online form. The following items are to be saved into one (1) pdf file and emailed directly to CRS Program Manager, Linda Schmitt by January 15.

  • Name and contact details of the second nominating sponsor.
  • A 200-word summary citation outlining the case for the award of fellow.
  • A two-page (2) document highlighting the specific distinguished and sustained contributions of the applicant to the fields of delivery science and technology within the past 10 years. In particular, the nomination should show evidence of the nominee’s leadership, discuss three (3) key publications/patents and/or industrial/regulatory/managerial contributions by the nominee (e.g. marketed products, creation of companies, leadership in the development of regulatory guidelines, methods and technologies) and, if appropriate, describe the nominee’s service to the CRS (e.g. governance, organization of symposia and sessions, committee participation, editorships).
  • A curriculum vitae (maximum 20 pages) that provides documentation of excellence as described in the two-page summary. The CV should include a list of awards (differentiating team versus singular recognition), refereed and non-refereed publications (indicating when the individual was the corresponding author and which publications were not from a refereed source), patents, invited presentations and grants.  Of importance is the documentation of leadership in each of these cited activities or how the achievement was dependent upon the contributions of the candidate.
  • Two (2) letters of support – one from the nominator and one from another CRS member – no longer than one (1) page each. The letter writers should indicate how long and in what capacity they have known the candidate. The letters should address the criteria above, noting the length, breadth, depth and impact of the contribution, and why the contributions would be rated as outstanding.

Selection Process:

The College of Fellows Selection Committee will select 5-10 candidates from submissions. The election of Fellows is determined by electronic ballot sent to all members of the College.

Award:

The awardee(s) will be recognized at the CRS Annual Meeting & Exposition during the Opening Session/Award Ceremony.

Past Recipients 

College of Fellows awardees

© Copyright Controlled Release Society  | Contact Us - Report a Bad Link